{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:37Z","timestamp":1793118277264,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>A 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patient concerns<\/jats:title><jats:p>The patient experienced chest pain for 2\u00a0months before diagnosis. Initial CT scans revealed multiple lung nodules, enlarged lymph nodes, and pleural effusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>The diagnosis was confirmed as advanced NSCLC the left upper lobe of the lung with specific genetic alterations, including EGFR 19del, EGFR amplification, and TPR-NTRK1 fusion, through molecular testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Prior treatments included the first-line therapy gefitinib (250\u00a0mg\/day) administered from September 2020 to June 2021, targeting the EGFR 19del mutation, achieving a partial response (PR). The second-line therapy osimertinib (80\u00a0mg\/day) was administered from July 2021 to January 2022, targeting EGFR 19del and T790M mutations, with a progression-free survival (PFS) of approximately 7\u00a0months. The third-line therapy almonertinib, another third-generation EGFR-TKI, was administered from January 2022 to March 2022, but the response was poor, leading to further progression. After identifying NTRK fusion and EGFR amplification, the patient was administered larotrectinib as third-line treatment. Prior treatments included targeted therapies and chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>Despite multiple lines of targeted therapy, the patient experienced rapid disease progression at several points, highlighting the challenges in managing NSCLC with complex genetic alterations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case underscores the importance of ongoing molecular testing and the potential need for combination therapies in managing advanced NSCLC with resistance to multiple targeted treatments. The current treatment with camrelizumab combined with chemotherapy shows promise, but further monitoring is necessary.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1571777","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:31:37Z","timestamp":1754458297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Jielin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenkang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cllc.2020.10.013","article-title":"NTRK fusion-positive non-small-cell lung cancer: the diagnosis and targeted therapy","volume":"22","author":"Haratake","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.3390\/ijms20153821","article-title":"Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)","volume":"20","author":"Hsu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2022.01.014","article-title":"Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer","volume":"166","author":"Huang","year":"2022","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1038\/oncsis.2017.17","article-title":"MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells","volume":"6","author":"Jakobsen","year":"2017","journal-title":"Oncogenesis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100462","DOI":"10.1016\/j.jtocrr.2023.100462","article-title":"The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations","volume":"4","author":"Kagawa","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.3390\/cancers15215248","article-title":"Tailoring therapeutic strategies in non-small-cell lung cancer: the role of genetic mutations and programmed death ligand-1 expression in survival outcomes","volume":"15","author":"Kobayashi","year":"2023","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.cllc.2020.10.003","article-title":"Emergence of NOTCH2-NTRK1 after osimertinib in a patient with lung adenocarcinoma with neuroendocrine differentiation","volume":"22","author":"Lin","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"864666","DOI":"10.3389\/fonc.2022.864666","article-title":"NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J. Thorac. Oncol. Official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol. Lond. Engl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.21037\/atm-22-2436","article-title":"Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy","volume":"10","author":"Song","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-Mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"107994","DOI":"10.1016\/j.celrep.2020.107994","article-title":"Inhibition of MEK1\/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-Driven cancer","volume":"32","author":"Vaishnavi","year":"2020","journal-title":"Cell Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12967-022-03593-3","article-title":"RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"20","author":"Wang","year":"2022","journal-title":"J. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41388-018-0454-2","article-title":"Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CCO.0000000000000805","article-title":"Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer","volume":"34","author":"Zeng","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40246-021-00320-9","article-title":"Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC)","volume":"15","author":"Zhou","year":"2021","journal-title":"Hum. Genomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1571777\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:31:38Z","timestamp":1754458298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1571777\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":25,"alternative-id":["10.3389\/fphar.2025.1571777"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1571777","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1571777"}}